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Abstract 
CYP3A5 and ABCB1 polymorphisms have been shown to influence tacrolimus blood concentrations and dose 
requirements, but the conclusion in the current reports were inconformity. Sirolimus are also metabolized by CYP3A 
subfamily and are substrates of the P-gp. The aim was to determine whether these polymorphisms affect tacroli-
mus (TAC) and sirolimus (SRL) trough concentrations and dose requirements after renal transplantation. 153 renal 
transplant recipients were enrolled into this study, 112 were treated with TAC-based regimen, Another 43 recipients 
received SRL-based regimen. The recipients’ mean follow-up time was 20 mo (range 15–27 mo). All renal transplant 
recipients were all in a stable stage. The trough concentration and daily dose of TAC and SRL were gained from each 
recipient. All recipients were genotyped for CYP3A5 (6986A>G), CYP3A4 intron 6 (CYP3A4*22), CYP3A4*18, ABCB1 
exon 26 (3435C>T), exon 12 (1236C>T) and 2677G>T/A SNPs by HRM analysis (high-resolution melting curve analy-
sis). The TAC and SRL concentration/dose ratio (C/D) in recipients with CYP3A5 (*)3/(*)3 were significantly higher than 
that of those with (*)1 allele (P < 0.05). However, there was no significant correlation between adjusted TAC and SRL 
trough concentrations or dose requirements with CYP3A4 and ABCB1 SNPs genetic polymorphisms. In recipients with 
TAC-based or SRL-based therapy, the CYP3A5 genes (6986A>G) can influence the TAC and SRL pharmacokinetics in 
renal transplant recipients.
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Background
The calcineurin inhibitors (CNI), tacrolimus (TAC) are 
the most widely used immunosuppression drugs to pre-
vent allograft rejection after solid organ transplantation. 
Both these drugs display a narrow therapeutic index 
and high inter-individual pharmacokinetic variability, so 
monitoring their blood levels is required to avoid rejec-
tion and reduce toxicity (López-Montenegro Soria et al. 
2010). Sirolimus (SRL) is another immunosuppressant by 
replacing the CNIs to prevent progression in chronic kid-
ney disease (CKD) following organ transplantation. SRL 
pharmacokinetics also exhibits wide subject variability 
(Sam et al. 2011).
The calcineurin-inhibitor TAC and SRL undergo exten-
sive first-pass metabolism in the human liver. This pro-
cess is catalyzed by cytochrome P450 (CYP) 3A enzymes. 
CYP3A4 and CYP3A5 have been identified as the major 
enzymes responsible for the metabolism of CNI and 
SRL in CYP3A subfamilies. On the other side, both CNI 
and SRL are the substrates of P-gp, an efflux transporter 
encoded by the MDR1/ABCB1 [adenosine triphosphate 
(ATP) binding cassette subfamily B, member 1] gene, 
which actively transports common drugs from the intra-
cellular to the extracellular domain and thereby influenc-
ing their pharmacokinetics (Sakaeda et al. 2003).
Studies reported that the single-nucleotide polymor-
phisms (SNPs) of genes encoding CYP3A4, CYP3A5 
and ABCB1 could be important determinants of CNI 
and SRL bioavailability and metabolism (Sakaeda et  al. 
2003; Lukas et  al. 2010; Mourad et  al. 2006; Li et  al. 
2006). In the general population, it is estimated that 
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genetics accounts for 20–95 % of the variability in drug 
disposition and effects (Evans and McLeod 2003). Some 
of the most commonly studied ABCB1, CYP3A4 and 
CYP3A5 variants include ABCB1 1236C>T, 2677G>T/A, 
3435C>T, CYP3A4 392A>G and CYP3A5 6986A>G. 
Among all those variants, the polymorphic CYP3A5 
6986A>G plays a major role. The G>A mutation in 
intron three results in a splice defect of the mRNA and 
produces an unstable and non-functional protein. The 
mutated allele was named CYP3A5*3 and the wild type 
was assigned CYP3A5*1. Those recipients bearing at 
least one active CYP3A5*1 required higher doses of tac-
rolimus to achieve therapeutic plasma concentrations 
than CYP3A5 non-expressors (MacPhee et al. 2005). The 
ABCB1 1236C>T and 3435C>T are synonymous SNPs, 
those two SNPs were correlated with ABCB1 function 
and resulted in substrate specificity changes (Letourneau 
et al. 2005; Brinkmann 2002). The impact of ABCB1 poly-
morphisms to the inter-individual variability in the blood 
concentration of CNI and SRL were partly controversially 
discussed.
The acute rejection was gonging down by the introduc-
tion of immunosuppression drugs, while the longtime 
survival rate was not increasing. The reason was the drug 
overuse and drug toxicity after longtime using. Therefore, 
we performed a clinical study to investigate the impact of 
the CYP3A5, CYP3A4 and ABCB1 genotypes on the dose 
requirement and pharmacokinetics of CNI and SRL in 
stable kidney transplant recipients receiving maintenance 
treatment, aimed to draw up individual treatment regi-
men for every recipient and reduced drug toxicity.
Methods
The inclusion of renal transplant recipients
This study was approved by the Ethics Committee of 
Chinese Human Genome and the Ethics Commit-
tee of West China Hospital, and written informed con-
sent was obtained from all recipients. We included 112 
recipients who received a first kidney graft in West 
China Hospital. The TAC and SRL treated recipients 
were received the induction therapy with alemtuzumab. 
Among all the renal transplant recipients, 112 recipi-
ents received a tacrolimus (TAC, Prograf ) based regi-
men (TAC+MMF+steroid), The initial oral daily dose 
of tacrolimus was 0.04 ~ 0.08 mg/(kg*d). The daily dose 
was adjusted according to the blood trough tacrolimus 
concentration (C0); the target trough concentration was 
5–10  ng/mL. After 3  months, target C0 was decreased 
to 3–6 ng/mL for long-term maintenance. In addition to 
tacrolimus, the recipients received MMF and steroids at 
a standard dosage regimen. 1500 mg/d MMF was given 
as two equally divided doses. The steroid regimen was 
1000 mg of i.v. methylprednisolone at the time of surgery 
and 500 mg/d i.v. the next 2 d. This schedule was followed 
by 80 mg/d of oral prednisone, progressively tapered by 
10 mg/d to 20 mg per day until 3 months after transplan-
tation, reduced to a maintenance dose of 5  mg daily or 
withdrawn. All recipients received tacrolimus based regi-
men for more than 1 month. All the recipients have ever 
happened acute rejection.
The other 43 recipients received a sirolimus (SRL, 
Rapamune) based regimen (SRL+MMF+steroid), The 
initial oral daily dose of sirolimus was 0.04  ~  0.06  mg/
(kg*d). Steroid and MMF therapy was the same as the 
tacrolimus regimen. SRL dose was adjusted to maintain a 
blood trough level of 5–10 ng/mL.
The recipients received sirolimus based regimen or 
TAC based regimen for more than 1 month and in sta-
ble state without rejection. The demographic and clinical 
characteristics of the recipients were listed in Table 1.
Genomic DNA extraction
Blood samples (3 mL) were collected in EDTA tubes and 
genomic DNA was isolated from whole blood samples 
using the whole blood DNA kit (Biotake corporation, 
Beijing, China). DNA was extracted from 200 µL of the 
whole bloods according to the manufacturer’s protocol. 
The concentration of DNA was diluted to 10  ng/µL for 
working solutions and the isolated DNA was stored at 
−20 °C.
Polymerase chain reaction and high‑resolution melting 
method
CYP3A5, CYP3A4 and ABCB1 SNPs were assessed. 
Some samples were previously genotyped by sequenc-
ing as controls for the SNPs. The polymerase chain reac-
tion (PCR) and melting curve analyses were performed 
under the same conditions in a 96-well plate on the 
Light Cycler480 (Roche Diagnostics, Penzberg, Bavaria, 
Germany). The primers were designed into a small frag-
ment surrounding the polymorphisms and avoiding 
the presence of other sequence variations in the primer 
region. The reaction mixtures contained 1.0 µL purified 
genomic DNA (10 ng/µL), 0.1 µL forward primer, 0.1µL 
reverse primer, 5µL Roche Mix (including 20  ×  EVA-
GREEN, dNTP, Hot Star Taq® Plus DNA Polymerase, 
10 × buffer), 1.4 µL 25 mM Mgcl2 and 2.4 µL H2O. Real-
time PCR was performed under the following conditions: 
an initial denaturation step at 95  °C for 15 min, contin-
ued with 50 cycles of 95  °C for 10 s, 60  °C for 15 s, and 
72  °C for 20  s. After the amplification phase, a melting 
curve analysis was performed at 95 °C for 1 min, 40 °C for 
1 min, 65 °C for 1 s, followed by slow heating at 0.01 °C/s 
to 95  °C. Collected data were analyzed by the LightCy-
cler 480 Gene Scanning software v1.2 (Roche Diagnos-
tics). Temperature shifting by selecting threshold, then 
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automatic grouping by calculation. The exactly same set-
ting of the normalization was used for all experiments. 
The genotype of subset was defined according to known 
genotypes of controls.
Immunosuppression drug blood concentration and other 
laboratory tests measurement
CNI (tacrolimus and cyclospine) dosage was given 
twice daily in equal amounts at 08:00 and 20:00 h. Blood 
samples were collected exactly before morning doses 
of CNI for determination of trough blood concentra-
tions (C0). Sirolimus dosage was given once daily and 
the trough concentration was tested before taking drug. 
Those drug concentrations were tested by an automated 
enzyme immunoassay (SIEMENS V-Twin) analyzer. 
Dose-adjusted trough blood concentrations (C/D ratio) 
were calculated by dividing the C0 (ng/mL) by the cor-
responding 24-h dose per kilogram basis (mg/kg body 
weight). We obtained serum levels of Cystatin-C, alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), bil-
irubin, and creatinine (Roche Diagnostics, Roche, Swit-
zerland), along with the trough level of those drugs.
Statistical analysis
Data were expressed as mean ±  SD or median (range). 
Analysis was performed using SPSS 16.0 statistical soft-
ware (SPSS Inc., Chicago, IL, USA). The Chi-square test 
was used to examine the difference in categorical data. 
The Mann–Whitney U test and Kruskal–Wallis test were 
employed to determine the difference in continuous val-
ues among groups. The allele and genotype frequencies 
of the CYP3A and ABCB1 polymorphisms were assessed 
for deviation from the Hardy–Weinberg equilibrium 
using the Chi-square test. A P value of <0.05 was consid-
ered statistically significant.
Results
The demographic and clinical characteristics of the 
recipients
There was no significant difference in age and gender 
among the three groups (Table  1). The recipients used 
CNI for a longer time than the recipients used sirolimus. 
After using those drug for over 1 month, the drug con-
centration in those recipients were stable, with 4.5 (3.9–
5.8) ng/mL for TAC and 5.9 (3.5–8.3) ng/mL for SRL.
Most of the renal transplant recipients used SRL were 
initially considered candidates for TAC to SRL conver-
sion because of renal dysfunction. After conversion 
to SRL for more than 1 month, the renal function has 
turned better for those recipients, the SCr was lowest in 
SRL group 1.20 (1.06–1.76) mg/dL among TAC group 
1.43 (1.08–2.14) mg/dL, without a significant increas-
ing in proteinuria (P < 0.05). In the mean time, the blood 
pressures (systolic pressure and diastolic pressure) were 
higher in CNI regimen treated group (P > 0.05).
On the other side, sirolimus has its own side effects. 
Firstly, we found that the recipients used sirolimus 
occurred hyperlipemia with significantly increasing in 
Cholesterol than the recipients used CNI. Second, ALT 
and AST level in those recipients used SRL were signifi-
cantly higher than the recipients used CNI, although in 
the normal range (P < 0.005). (Table 1).
Tacrolimus
Among the 112 TAC treated recipients,there were 52 
CYP3A5 6986A>G*1/*1 and *1/*3 (expressors) geno-
type and 60 *3/*3 (non-expressors) genotype. The 
CYP3A5*1/*1 and *1/*3 genotypes were combined, as 
these represent the CYP3A5 expressers category, we 
found no significant difference between the CYP3A5*1/*1 
and *1/*3 genotypes groups and *3/*3 genotype was 
kept in the non-expressers category. The C/D ratios in 
*1/*1+*1/*3 recipients [124(113–165.4)] were much 
lower than *3/*3 recipients [184 (148–261)] (P  <  0.05, 
Table 2). In the mean time, the recipients with CYP3A5*1 
allele (expressor) need higher TAC dose [2.7 (1.7–2.9)] 
than *3/*3 recipients [2.3 (1.6–2.9)], (P  <  0.05, Table  2). 
When multiple binary logistic regression analysis was 
carried out to assess the baseline clinical covariates (age, 
gender, BMI of recipients, HLA, preoperative creatinine 
and urine volume, dialysis time), it did not modify the 
Table 1 Demographic and  clinical characteristics of  renal 
transplant recipients treated by TAC and SRL
The datas were expressed as median (range)
* P < 0.05 compared with SRL group
TAC SRL
Number (N) 112 43
Age (years) 35 (31–46) 35 (34–46)
Sex (male/female) 70/42 30/13
Therapy time (month) 11 (7–20)* 6 (4–10)
Concentration (ng/mL) 4.5 (3.9–5.8) 5.9 (3.5–8.3)
Glucose (mmol/L) 4.81 (4.6–5.2) 5.09 (4.86–5.77)
Systolic pressure (mmHg) 132 (126–140) 126 (110–138)
Diastolic pressure (mmHg) 98 (67–117) 87 (65–106)
ALT (IU/L) 18.6 (14.2–25.8)* 26 (18–37.5)
AST (IU/L) 23 (16.3–26)* 25.5 (20.5–36.2)
Cholesterol (mg/dL) 4.67 (3.97–5.51)* 5.4 (4.92–5.77)
Triglyceride (mg/dL) 1.23 (0.98–2.14) 1.68 (1.09–2.21)
Creatinine (mg/dL) 1.4 (1.08–2.14)* 1.20 (1.06–1.76)
Proteinuria (g/mL) 0.2 (0.1–0.5) 0.3 (0.2–0.7)
Imunosuppressive TAC/MMF/ SRL/MMF/
Regimen Prednisolone Prednisolone
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association between the CYP3A5 genotype and the asso-
ciation of C/D ratios (P = 0. 03),
For the ABCB1 3435C>T, there were 30 CC geno-
type,62 CT genotype and 20 TT genotype. There was no 
significant difference between different genotype. For the 
ABCB1 1236 C>T, with 17 CC genotype, 50 CT geno-
type, 45 TT genotype. For the ABCB1 2677 C>T/A, with 
22 CC genotype, 49CT genotype, 16 TT genotype and 
25 with A genotype. We did not found any association 
between ABCB1 SNPs and TAC pharmacokinetics index.
For the CYP3A4 intron 6(CYP3A4*22), There was only 
one genotype CC in Chinese renal transplant recipients.
For the CYP3A4*18, there was only 2 mutation was 
found and there number was too small to calculate.
Sirolimus
Among the 43 SRL treated recipients,there were 20 
CYP3A5 6986A>G*1/*1 and *1/*3 (expressors) and 
23 *3/*3 (non-expressors). The dose/trough concen-
tration ratios in *1/*1 and *1/*3 recipients [249 (248–
409.6)] were much lower than *3/*3 recipients [389.1 
(293.7–537.9)] (P < 0.05). In the mean time, the recipients 
with CYP3A5*1 allele (expressor) need higher TAC dose 
[1.28 (1.00–1.56)] than *3/*3 recipients [1.0 (1.0–1.0)], 
(P < 0.05, Table 2). When multiple binary logistic regres-
sion analysis was carried out to assess the baseline clini-
cal covariates (age, gender, BMI of donors and recipients, 
HLA, PRA, preoperative creatinine and urine volume, 
dialysis time), it did not modify the association between 
the CYP3A5 genotype and the association of C/D ratios 
(P = 0. 02).
For the ABCB1 3435C>T, there were 18 CC genotype, 
20 CT genotype and 5 TT genotype. There was no sig-
nificant difference between different genotype. For the 
ABCB1 1236 C>T, with 8 CC genotype, 20 CT geno-
type,15 TT genotype. For the ABCB1 2677 C>T/A, with 
7 CC genotype, 16 CT genotype, 11 TT genotype and 
9 with A genotype. We did not found any association 
between ABCB1 SNPs and TAC pharmacokinetics index.
For the CYP3A4 intron 6(CYP3A4*22) and 
CYP3A4*18, There was only one genotype CC in Chinese 
renal transplant recipients.
Table 2 The effects of  CYP3A4, CYP3A5 and  ABCB1 genetic polymorphisms on  tacrolimus and  sirolimus daily require-
ments, concentration/dose ratio after renal transplantation
The datas were expressed as median (range)
* P < 0.05 compared with *1/*1+*1/*3
Tacrolimus Sirolimus












CYP3A5 (6986A>G) 112 43
*1/*1+*1/*3 52 2.7 (1.7–2.9) 6.2 (5.6–7.4) 124 (113–165.4) 20 1.28 (1.00–1.56) 4.2 (5.75–7.2) 249 (248.7–409.6)
*3/*3 60 2.3 (1.6–2.9)* 6.8 (4.5–8.7) 184.4 (148–261.7)* 23 1.00 (1.00–1.00)* 4.0 (5.7–7.7) 389.1 (293.7–537.9)*
ABCB1 3435C>T
 CC 30 1.0 (1.0–3.2) 4.3 (1.9–6.8) 242.1 (110.2–374) 18 1.00 (1.00–1.00) 7.1 (5.1–7.6) 364.5 (310.6–574.3)
 CT 62 1.25 (1.3–2.1) 6.2 (4.1–7.5) 165.2 (115.9–205) 20 1.10 (1.00–1.20) 6.2 (3.3–7.8) 365.6 (177.6–498.6)
 TT 20 1.5 (1.0–2.0) 7.1 (5.5–10.2) 324 (214.1–559) 5 1.00 (0.65–1.5) 4.3 (3.75–6.75) 316.5 (217.9–549.8)
ABCB1 1236C>T
 CC 17 1.0 (1.0–2.0) 6.0 (3.7–9.5) 247 (104.6–441) 8 1.00 (1.00–1.75) 5.7 (3.0–7.1) 298.6 (128.6–364.6)
 CT 50 1.5 (1.0–2.0) 7.1 (5.7–8.5) 181.1 (142.8–268) 20 1.00 (1.00–1.50) 7.5 (4.8–7.9) 385.9 (264.8–628.9)
 TT 45 1.3 (1.1–2.0) 5.0 (3.9–5.4) 214 (167–245) 15 1.00 (0.9–1.00) 5.2 (4.1–7.5) 381.9 (278.6–48.9)
ABCB1 2677C>T/A
 CC 22 1.0 (1.0–2.0) 6.0 (3.7–9.5) 217 (104.6–441) 7 1.00 (1.00–1.75) 5.7 (3.0–7.1) 298.6 (128.6–364.6)
 CT 49 1.15 (1.0–2.0) 7.1 (5.7–8.5) 161.1 (142.8–268) 16 1.00 (1.00–1.50) 6.5 (4.8–7.9) 386.9 (264.8–628.9)
 TT 16 1.25 (1.1–2.0) 5.0 (3.9–5.4) 204 (167–245) 11 1.00 (0.9–1.00) 4.2 (4.1–7.5) 371.9 (278.6–48.9)
A 25 1.3 (1.1–2.0) 5.0 (3.9–5.4) 214 (167–245) 9 1.00 (0.9–1.00) 5.2 (4.1–7.5) 341.9 (278.6–48.9)
CYP3A4 (CYP3A4*22)
 CC 112 2.0 (1.0–2.0) 6.5 (5.2–8.7) 205.2 (126.9–324) 43 1.07 (0.86–1.65) 6.1 (5.3–7.8) 364.8 (248.7–525.8)
CYP3A4 (CYP3A4*18)
 TT 110 2.0 (1.0–2.0) 6.5 (5.2–8.7) 205.2 (126.9–324) 43 1.07 (0.86–1.65) 6.1 (5.3–7.8) 364.8 (248.7–525.8)
 CT+TT 2 2.0/3.0 7.0/6.4 214/323 0 / / /
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Renal function
We found no significant effect of the recipients CYP3A5 
and ABCB1 genotypes on the eGFR of TAC or SRL 
treated regimen.
Discussion
Tacrolimus and sirolimus have become important immu-
nosuppressive drugs in the field of organ transplantation. 
However, both those drugs exhibit a low bioavailability and 
there is a large inter-individual variability in their phar-
macokinetics. The pharmacogenetics of genetic polymor-
phisms in drug metabolizing gene played an important 
role in interindividual differences of drug bioavailability.
Tacrolimus
In this study, we found CYP3A5 played an important 
role in the pharmacokinetics of TAC. The dose of tac-
rolimus was higher in the recipients with CYP3A5*1 
allele (expressor) than the recipients with CYP3A5*3 
allele (non-expressor), and the concentration/dose ratio 
was lower in CYP3A5*1 allele (expressor). Several stud-
ies have observed the association between this CYP3A5 
gene polymorphism and the tacrolimus dose requirement 
and indicate that CYP3A5 expressers require a larger tac-
rolimus dose in order to maintain the same blood con-
centration (Rong et  al. 2010; Singh et  al. 2009; Renders 
et al. 2007; Kuypers et al. 2007; Zhang et al. 2005). It is 
important to draw up different treatment plan for differ-
ent recipients of different race.
The starting dose for the recipients was subsequently 
adjusted according to blood concentration in clinical, 
but the problem was that CYP3A5 expressers exhibited 
a mean tacrolimus blood level much lower than the tar-
get. Conversely, the non-expressers had higher tacroli-
mus trough concentrations than the target concentration, 
which may induce side effects such as hyperglycemia, 
nephrotoxicity and infection. In our study, we found the 
expressers need 1.3 ~ 1.5 fold dose than the unexpress-
ers in Chinese renal transplant recipients (Zhang et  al. 
2005). CYP3A5 genotype analysis could be performed 
prior to transplantation in order to help the initial dosing 
of tacrolimus.
The results from previous studies on the relationship 
between the ABCB1 polymorphism and tacrolimus phar-
macokinetics are controversial. The present study we 
have not found a significant influence of ABCB1 C3435T 
polymorphism on tacrolimus dose requirement for renal 
transplant recipients. Several previous studies have 
drawn similar conclusions that the genotype or haplotype 
of ABCB1 influences the tacrolimus dose requirement. 
Subsequent studies, however, fail to prove such an associ-
ation (Mourad et al. 2006; Li et al. 2006; Rong et al. 2010; 
Haufroid et al. 2006).
Sirolimus
The study on sirolimus was limited by the smaller sam-
ple size. Similar to tacrolimus, the dose/trough ratio 
was lower in CYP3A5-expressors compared with non-
expressors.The mean higher dosage administered in this 
group. The data on the impact of CYP3A5 on sirolimus 
dose requirement, however, are contradictory (Lukas 
et  al. 2010; Renders et  al. 2007; Mourad et  al. 2005; 
Le Meur et  al. 2006; Miao et  al. 2008; Zochowska et  al. 
2012). Recently, Le Meuer et  al. (Le Meur et  al. 2006) 
confirmed that CYP3A5 expressors require significantly 
higher sirolimus doses to reach the C0 target range than 
non-expressors. Accordingly, Anglicheau et  al. demon-
strated that sirolimus concentration/dose ratio was lower 
in CYP3A5 expressors than in non-expressors, whereas 
Mourad et al. (Mourad et al. 2005) showed no significant 
correlation between adjusted sirolimus trough concen-
trations or dose requirements and genetic polymorph-
isms. Genetic variants of efflux transporters seemed to 
play a minor role, as there was no significant influence of 
ABCB1 or ABCC2 polymorphisms on the pharmacoki-
netics of sirolimus (Hebert et  al. 2003; Hesselink et  al. 
2004; Elens et al. 2014; Hesselink et al. 2014).
In conclusion, CYP3A5*3 SNP was significantly cor-
related with TAC and SRL dose requirement and dose-
adjusted concentrations in renal transplant recipient s of 
China. CYP3A5 expressers were associated with lower 
C/D rations and thereby require higher TAC and SRL 
dose to achieve therapeutic concentration compared with 
non-expressors. Performing CYP3A5 genotyping prior 
to transplantation is helpful for drug selection and dos-
ing and thus could contribute to a better-individualized 
immunosuppressive therapy.
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